AU752004B2 - Recombinant Rhabdovirus containing a heterologous fusion protein - Google Patents

Recombinant Rhabdovirus containing a heterologous fusion protein Download PDF

Info

Publication number
AU752004B2
AU752004B2 AU19056/99A AU1905699A AU752004B2 AU 752004 B2 AU752004 B2 AU 752004B2 AU 19056/99 A AU19056/99 A AU 19056/99A AU 1905699 A AU1905699 A AU 1905699A AU 752004 B2 AU752004 B2 AU 752004B2
Authority
AU
Australia
Prior art keywords
protein
rhabdovirus
recombinant
cells
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19056/99A
Other languages
English (en)
Other versions
AU1905699A (en
Inventor
Clinton S. Robison
Michael A. Whitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of AU1905699A publication Critical patent/AU1905699A/en
Priority to AU2002300207A priority Critical patent/AU2002300207B2/en
Application granted granted Critical
Publication of AU752004B2 publication Critical patent/AU752004B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU19056/99A 1997-12-22 1998-12-22 Recombinant Rhabdovirus containing a heterologous fusion protein Ceased AU752004B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002300207A AU2002300207B2 (en) 1997-12-22 2002-07-19 Recombinant Rhabdovirus containing a heterologous Fusion Protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
US60/068472 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002300207A Division AU2002300207B2 (en) 1997-12-22 2002-07-19 Recombinant Rhabdovirus containing a heterologous Fusion Protein

Publications (2)

Publication Number Publication Date
AU1905699A AU1905699A (en) 1999-07-12
AU752004B2 true AU752004B2 (en) 2002-09-05

Family

ID=22082797

Family Applications (2)

Application Number Title Priority Date Filing Date
AU19056/99A Ceased AU752004B2 (en) 1997-12-22 1998-12-22 Recombinant Rhabdovirus containing a heterologous fusion protein
AU2002300207A Ceased AU2002300207B2 (en) 1997-12-22 2002-07-19 Recombinant Rhabdovirus containing a heterologous Fusion Protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002300207A Ceased AU2002300207B2 (en) 1997-12-22 2002-07-19 Recombinant Rhabdovirus containing a heterologous Fusion Protein

Country Status (14)

Country Link
US (2) US6497873B1 (enExample)
EP (1) EP1040198B1 (enExample)
JP (1) JP4544497B2 (enExample)
AP (1) AP1968A (enExample)
AT (1) ATE451466T1 (enExample)
AU (2) AU752004B2 (enExample)
BR (1) BR9814370A (enExample)
CA (1) CA2316033A1 (enExample)
DE (1) DE69841372D1 (enExample)
IL (2) IL136905A0 (enExample)
MX (1) MXPA00006184A (enExample)
NZ (1) NZ505312A (enExample)
OA (1) OA11432A (enExample)
WO (1) WO1999032648A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320239T3 (es) * 1999-09-17 2009-05-20 Wellstat Biologics Corporation Virus oncolitico.
WO2002016437A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
JP2004537279A (ja) * 2001-03-09 2004-12-16 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 感染性ｃ型肝炎ウイルス合成のための細胞培養システム
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
WO2005016961A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
AU2004250129A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA
EP2064229B1 (en) * 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2009014878A2 (en) * 2007-07-06 2009-01-29 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US20100215691A1 (en) * 2009-02-20 2010-08-26 Parks Christopher L Recombinant viral vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013158263A1 (en) 2012-04-18 2013-10-24 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
KR20200003160A (ko) * 2017-05-03 2020-01-08 바이오마린 파머수티컬 인크. 조혈모세포의 형질도입을 위한 개선된 렌티바이러스
IL263979B2 (en) 2017-05-10 2023-09-01 Wellstat Immuno Therapeutics Llc Viruses with an envelope resistant to the immune system for cancer treatment
JP2023513135A (ja) * 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
WO2023051607A1 (zh) * 2021-09-29 2023-04-06 上海行深生物科技有限公司 病毒培养方法

Also Published As

Publication number Publication date
CA2316033A1 (en) 1999-07-01
EP1040198B1 (en) 2009-12-09
AU1905699A (en) 1999-07-12
JP2001526901A (ja) 2001-12-25
AP1968A (en) 2009-04-30
WO1999032648A1 (en) 1999-07-01
AP2000001852A0 (en) 2000-06-30
US6497873B1 (en) 2002-12-24
NZ505312A (en) 2003-01-31
US20030138457A1 (en) 2003-07-24
MXPA00006184A (es) 2003-02-11
ATE451466T1 (de) 2009-12-15
DE69841372D1 (de) 2010-01-21
AU2002300207B2 (en) 2006-07-13
IL136905A (en) 2007-10-31
BR9814370A (pt) 2000-10-10
EP1040198A1 (en) 2000-10-04
OA11432A (en) 2004-04-26
JP4544497B2 (ja) 2010-09-15
IL136905A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU752004B2 (en) Recombinant Rhabdovirus containing a heterologous fusion protein
Robison et al. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly
Johnson et al. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
JP4434478B2 (ja) リエンジニアリングされた外被を有するラブドウイルス
EP3704136B1 (en) Adapter-based retroviral vector system for the selective transduction of target cells
US20230190917A1 (en) Viral vaccine vector for immunization against a betacoronavirus
Mebatsion et al. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein.
EA032403B1 (ru) Лентивирусные векторы, псевдотипированные гликопротеином оболочки вируса синдбис
JPH10501403A (ja) 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入
US7041489B2 (en) Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof
Ma et al. Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism
WO2024000223A1 (zh) 经改造的病毒包膜蛋白及其用途
US20240342266A1 (en) Method for treating tumor with combination of exogenous antigen and therapeutic agent
AU2006225325B2 (en) Recombinant Rhabdovirus containing a heterologous fusion protein
Roberts et al. Redesign and genetic dissection of the rhabdoviruses
US7994295B2 (en) Recombinant viruses comprising the membrane-proximal domain of VSV G protein
Johnson Assembly of foreign proteins into the envelope of vesicular stomatitis virus: Vaccine and targeting applications
Chai Identification of a receptor for an avian retrovirus and characterization of a novel gene delivery vector
Bertrand Understanding the mechanisms of entry of Jaagsiekte sheep retrovirus
Tochikura et al. Further Characterization of a CD99‐Related 21‐kDa Transmembrane Protein (VAP21) Expressed in Syrian Hamster Cells and Its Possible Involvement in Vesicular Stomatitis Virus Production
Robison IV Assembly and fusion-potentiation domains of the vesicular stomatitis virus glycoprotein and their utility in the development of cell-type-targeted rhabdoviral vectors
Boerger The use of retroviral vectors preloaded with a retroviral receptor-ligand bridge protein for cell-type-specific viral targeting and as a system for studying avian leukosis virus entry
HK1056576B (en) Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)